KLRK1 and sarcoma: While testing of NKG2D+ GM NK-92 cells against sarcoma explants did not yield any significant results (Figure S8), DNAM-1+ GM NK-92 cells exhibited significantly increased cytotoxicity compared to WT-NK-92 cells against all three sarcoma explants (HTT12, HTT25, and HTT26), which were simultaneously tested in the same assay (Figure 5A).